Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENGIC-01 COLOSOTO
2024-514030-20-00Phase 2Suspended
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, sotorasib and fluorouracil in colorectal adenocarcinoma, sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-free survival status at 8 months. Started Aug 2025; status: suspended.
02
Drugs
panitumumabsotorasibfluorouracil
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2024-514030-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514030-20-00.